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Adoptive immunotherapy with virus-speciﬁc T lymphocytes can efﬁciently reconstitute antiviral immunity
against cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus (ADV) without causing acute toxicity
or increasing the risk of graft-versus-host disease. To gain insight into antiviral T cell repertoires and to identify
the most efﬁcient antigens for immunotherapy, the frequencies of CMV-, EBV- and ADV-speciﬁc T cells in 204
HLA-typed healthy donors were assessed using viral peptides and peptide pools. Conﬁrmatory testing for CMV
serology by Western blot technique revealed 19 of 143 (13%) false-positive results. We observed highly
signiﬁcant individual and overall differences in Tcell frequencies against CMV, EBV, and ADV antigens, whereas
antigen-speciﬁc T cells were detected in 100% of CMV- seropositive donors, 73% of EBV- seropositive donors,
and 73% of ADV-seropositive donors. At least 124 (61%) potential T cell donors were identiﬁed for each virus.
Among the tested antigens, frequencies for CMVpp65 and EBVBZLF1 peptide pools were highest. Short-term
in vitro peptide stimulation revealed that a donor response to a certain ADV- and EBV-derived peptide may
not be determined without prior stimulation. A modiﬁed granzyme B ELISpot was used to detect T cell spec-
iﬁcity and alloreactivity. Treatment with allogeneic virus-speciﬁc cytotoxic T lymphocytes from seropositive
third-party donors may be a feasible therapeutic option for infections following cord-blood stem cell trans-
plantation or hematopoietic stem cell transplantation from virus-seronegative donors.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Donor lymphocyte infusions can be used to treat both
Major complications after hematopoietic stem cell
transplantation (HSCT), such as graft rejection and graft-
versus-host disease (GVHD), are encountered by HLA-high
resolution donor-recipient matching and T cell depletion
from stem cell grafts and treated by increased immunosup-
pression [1]. The conditioning regimens, even reduced-
intensity conditioning, account for a prolonged immune
recovery period of 3 to 6 months, during which the patient is
highly susceptible to infections normally controlled by T cell
immunity. Thus, infectious complications mainly caused by
endogenous herpesviruses, such as cytomegalovirus (CMV)
and Epstein-Barr virus (EBV), or lytic viruses, such as
adenovirus (ADV), are common and associated with mo-
mentous morbidity and mortality rates. CMV and EBV
infections occur in about 60% to 70% and 10% to 26% of SCT
recipients, respectively, and ADV infections in about 3% to
20%, with signiﬁcantly higher rates in pediatric patients
[2-4]. Pre-emptive therapy of CMV with ganciclovir or other
medication and treatment of EBVwith rituximab are possible
but do not yield restoration of the T cell repertoire.edgments on page 1490.
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13.07.015viral infections and leukemia relapses, but are associated
with potentially life-threatening GVHD and are unavailable
for patients receiving cord blood transplants. Furthermore,
treatment with donor lymphocyte infusions is not a thera-
peutic option for high-risk patients with seronegative
donors. It has recently been shown that the adoptive transfer
of antiviral cytotoxic T lymphocytes (CTLs) directed against
CMV [5-9], EBV [10-13], and ADV [14-16] isolated from
seropositive donors can rapidly reconstitute antiviral im-
munity after HSCT and organ transplantation without sig-
niﬁcant toxicity or GVHD. Infusions of T lymphocyte lines
enriched in multivirus (CMV, EBV, and ADV)-speciﬁc CTLs
reproducibly controlled infections by all 3 viruses and may
form the basis of future adoptive immunotherapy trials in
patients at risk for multiple infections [17-20].
Methods for direct selection of virus-speciﬁc T cells
without the need for ex vivo manipulation are attractive to
generate clinical-grade antiviral CTLs. The 2 main approaches
include the use of peptide-MHC (pMHC) multimers [21-24]
and cytokine secretion assays (eg, interferon-gamma [IFN-g]
secretion assay) [7-9,13,14,25]. The pMHC multimer tech-
nology requires knowledge of immunodominant HLA-
restricted peptides. Reversible pMHC multimer technologies
(streptamers, histamers) were developed to isolate antigen-
speciﬁc T cells without altering their functional status
[26,27]. Cytokine secretion assays are not subject to any HLATransplantation.
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overlapping peptides spanning whole immunodominant
proteins. They enable the generation of CD4þ and/or CD8þ
T cells responsive to multiple epitopes [25].
The isolation of antiviral T cells by the above-described
assays is restricted to antigens for which moderate or high
T cell frequencies are present in the peripheral blood of
potential T cell donors. Furthermore, it is still difﬁcult, labo-
rious, and time-consuming to generate antigen-speciﬁc
T cells from naïve T cell donors [28-30]. Therefore, alloge-
neic third-party T cell donors may serve as an alternative for
patients receiving allogeneic cord blood transplants, trans-
plants from virus-seronegative donors, or solid organ trans-
plants with limited HLA-match, for which donor blood
generally is not available. To gain more insight into virus-
speciﬁc memory T cell repertoires and to identify the most
efﬁcient target antigens for adoptive immunotherapy, we
determined the frequencies of antiviral T cells in 204 healthy
donors via IFN-g enzyme-linked immunospot (ELISpot) assay
and by ﬂow cytometric analysis using pMHC multimers.
Using these well-established methods of T cell monitoring
[31,32], we assessed the T cell frequencies against peptides
and peptide pools available in good manufacturing practice
(GMP) quality, derived from viral proteins previously
demonstrated to be immunodominant or subdominant, eg,
phosphoprotein 65 (pp65) and immediate early (IE)-1 for
CMV [33-35], BZLF1, nuclear antigen [EBNA]-1) and latent
membrane protein 2A (LMP2 A) for EBV [36], and the ADV
major capsid protein, hexon [37]. Furthermore, a modiﬁed
granzyme B (GrB) ELISpot was established to determine the T
cell speciﬁcity and alloreactivity.
MATERIALS AND METHODS
Study Subjects and Preparation of Peripheral Blood Mononuclear Cells
Informed consent as approved by ethics committee of the Medical
School Hannover was obtained from 204 healthy donors (mean age,
42 years; range, 20 to 69 years) with awide HLA diversity, no prior history of
blood transfusion, and no signs of acute infection. Age and gender distri-
bution were as follows: male, n ¼ 156; mean age, 43 years; range 20 to
69 years; female, n ¼ 48; mean age, 40 years; range, 22 to 65 years. In all
donors, HLA class I and class II (4-digit) typing was performed by sequence-
based typing. Peripheral blood mononuclear cells (PBMCs) were resus-
pended in culture medium (CM) consisting of RPMI1640 (Lonza, Vervies,
Belgium) with 10% human AB serum (C.C.pro, Oberdorla, Germany). Samples
were cryopreserved in liquid nitrogen for further analysis.
Serological Testing by ELISA and Western Blot
The ELISA-based Abbott Architect CMV-IgG assay (Abbott Diagnostic,
London, UK) was routinely used to detect CMV-speciﬁc antibodies in donor
plasma. Additionally, plasma samples were tested using a commercial
Western blot assay designed as a conﬁrmatory assay to determine anti-CMV
(recomBlot CMV IgG) or anti-EBV (recomLine EBV IgG, both from Mikrogen,
Neuried, Germany) IgG antibodies. The alphaWell Adenovirus IgG ELISA
(Mikrogen) was used for qualitative determination of IgG antibodies against
ADV. Serological testing was performed at the time of the baseline T cell
assay and at 4 weeks and 3 months of follow-up. All donors were retro-
spectively tested for anti-EBV IgG antibodies by ELISA (Enzygnost anti-EBV-
IgG, Dade Behring, Newark, Denmark).
Flow Cytometric Analysis of Antiviral T Cells
Brieﬂy,1106 freshly isolatedPBMCswere stainedwiththephycoerythrin-
conjugated pentamers (Proimmune, Oxford, UK) representing 6 common HLA
molecules from different immunodominant proteins of CMV (A*02:01/
NLVPMVATV [pp65495-504, shortenedmA02-pp65] and A*01:01/YSEHPTFTSQY
[pp65363-373, mA01-pp65]); EBV (A*02:01/CLGGLLTMV [LMP2426-434, mA02-
LMP2], B*08:01/RAKFKQLL [BZLF1190-197, mB08-BZLF1], B*08:01/FLRGRAYGL
[EBNA-3A193-201, mB08-EBNA-3A], B*35:01/HPVGEADYFEY [EBNA-1407-417,
mB35-EBNA-1]); and ADV (A*01:01/TDLGQNLLY [hexon886-894, mA01-Hex],
A*24:02/TYFSLNNKF [hexon37-45, mA24-Hex] and B*07:02/KPYSGTAYNAL
[hexon114-124, mB07-Hex]), followed by staining with allophycocyanin-
conjugated monoclonal anti-CD8 antibody (mAb, Beckman Coulter, Miami,Florida) and phycoerythrin-Cy7-conjugated anti-CD19 (BD Biosciences, Hei-
delberg, Germany). Flow cytometric analyses were performed using a FACS-
CantoII ﬂow cytometer (BD Biosciences) and FACSDiva Software (V6.1.2). At
least 50,000 events in the lymphocytegatewereanalyzedand theproportionof
virus-speciﬁc pentamerþ/CD8þ cells was expressed as percentage of all
CD19-CD8þ lymphocytesanalyzed. Thegating strategyused for thedetectionof
virus-speciﬁc pentamerþ/CD8þ cells (A) and representative dot plots for each
pentamer (B) are shown in Supplementary Figure S-F1. For a population to be
considered positive, 1 of 2 conditions had to be met: (1) well-deﬁned cell
population, and/or (2) .3% pentamerþ/CD8þ cells. Scatteredgroupsof stained
cells were not sufﬁcient to be considered a positive population.
IFN-g ELISpot Assay for High-throughput Screening
MultiScreenﬁlterplates (MSIPS4W10,Millipore, Bedford,MA)were coated
overnightwith 1 mL/mL anti-IFN-gmAb1-D1K (Mabtech, Stockholm, Sweden)
and blocked with CM for 1 hour at 37C. Before performing ELISpot assays, the
optimal cell number was validated by cell titration using 1  105, 2  105,
2.5  105, 3  105, 4  105, and 5  105 PBMCs/well isolated from 4 different
donors (Supplementary Figure S-F2). Because 2.5  105 PBMCs/well were
identiﬁed in the range of linearity for all used peptide pools and the classiﬁ-
cation of the donors into the different responder groups by using 2.5  105
PBMCs/well remained stable at higher cell concentrations (Supplementary
Table S-T1), this cell number was used in all further ELISpot assays.
The 2.5  105 PBMCs were plated in 125 mL CM/well and incubated
overnight with 10 mg/mL CEF pool (positive control covering HLA class
Ierestricted T cell epitopes of CMV, EBV, and ﬂu virus (CEF peptides), PAN-
ATecs, Tuebingen, Germany), 10 mg/mL peptide and .6 nmoL of each peptide/
mL peptide pool (pp), respectively. Pools of the following overlapping
peptides were used to screen donors independent of HLA type: ppCMVpp65,
ppCMVIE-1, ppEBVEBNA-1, ppEBVLMP2 A, ppEBVBZLF1, and ppADV5hexon
(Miltenyi Biotec, Bergisch Gladbach, Germany).
IFN-g secretion was detected using biotin-conjugated antihuman IFN-g
antibodies (mAb 7-B6-1-biotin, Mabtech) and streptavidin-alkaline phos-
phatase (Mabtech) and revealed by 5-bromo-4-chloro-3-indolyl phosphate/
nitroblue tetrazolium (BCIP/NBT Liquid Substrate, Sigma-Aldrich, Hamburg,
Germany). Spots were counted using ImmunoScan Core Analyzer and
ImmunoSpot 5.0 Academic software (both from Cellular Technology Ltd.,
Bonn, Germany). Means of duplicate wells were calculated and expressed as
spots per well (spw)/2.5  105 PBMCs. Donors were divided into 3 groups as
follows: high responders (50 spw), low responders (10 spw to 50 spw),
and nonresponders (10 spw).
Peptide-speciﬁc Expansion of Antiviral T Cells
Frequencies of virus-speciﬁc T cells of 30 donors were determined before
stimulation (day 0) by HLA-matched pentamer staining and ELISpot using the
respective HLA-matched peptides. The following peptides were used with
regard to the donor’s HLA type: (1) CMV, A*02:01/NLVPMVATV (pp65495-504,
shortened pA02-pp65) andA*01:01/YSEHPTFTSQY (pp65363-373, pA01-pp65);
(2) EBV, A*02:01/CLGGLLTMV (LMP2426-434, pA02-LMP2), B*08:01/RAKFKQLL
(BZLF1190-197, pB08-BZLF1), B*08:01/FLRGRAYGL (EBNA-3A193-201, pB08-
EBNA-3A), and B*35:01/HPVGEADYFEY (EBNA-1407-417, pB35-EBNA-1); and
(3) ADV, A*01:01/TDLGQNLLY (hexon886-894, pA01-Hex), A*24:02/TYFSLNNKF
(hexon37-45, pA24-Hex), and B*07:02/KPYSGTAYNAL (hexon114-124, pB07-Hex)
(all ProImmune).
PBMCs were resuspended in CM supplemented with 50 U/mL IL-2
(PeproTech, Hamburg, Germany) at a concentration of 1  107 cells/mL
and stimulated with 10 mg/mL peptide. On day 7, cells were analyzed by
pentamer staining and IFN-g ELISpot using the speciﬁed peptides for over-
night stimulation.
Detection of IFN-g Secreting Cells by Cytokine Secretion Assay
Cytokine secretion assays were performed using PBMCs from 4 donors,
diluted at 1  107 cells/mL in CM and stimulated for 4 hours with
ppCMVpp65, ppEBVBZLF1, and ppADV5hexon at a ﬁnal concentration of 1 mg/
mL of each peptide/mL pp. Additionally, PBMCs from 7 donors were stim-
ulated with either ppCMVIE-1, ppEBVEBNA-1, and/or ppEBVLMP2A. The
assays were performed according to the manufacturer’s instructions (IFN-g
Secretion AssayeDetection Kit, Miltenyi Biotec). Anti-CD8- allophycocyanin
and anti-CD4-FITC mab (BD Biosciences) were used for staining. At least
20,000 events were acquired in the live gate for each analysis. Gates were
set based upon the scatter properties of lymphocytes and on IFN-gþ/CD3þ,
IFN-gþ/CD8þ, and IFN-gþ/CD4þ T cell populations.
Granzyme B and IFN-g ELISpot Assays to Determine Speciﬁcity and
Alloreactivity
T cells stimulated for 7 days with the respective peptides were tested for
killing of autologous and allogeneic PBMCs in IFN-g and GrB ELISpot assays.
IFN-g ELISpot plates were coated and developed as already described. The
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manufacturer’s instructions (Abcam, Cambridge, UK). Brieﬂy, PBMCs of HLA-
A*02:01-typed CMV-seropositive donors were plated at a density of 1 107
cells/mL in CM and stimulated with 10 mg/mL pA02-pp65 in the presence of
50 U/mL IL-2. After 7 days, cells were plated on precoated ELISpot plates at
a density of 2.5  105/well. Allogeneic or autologous unloaded or pA02-
pp65-loaded irradiated PBMCs were used as target cells (1  105 cells/
well; effector to target ratio ¼ 2.5:1). Positive controls consisted of PMA-
stimulated (phorbol 12-mysristate 13-acetate, 10 mg/mL, Sigma) and pA02-
pp65-stimulated T cells (10 mg/mL), respectively. For negative control, cells
were cultured in CM. After incubation at 37C for 16 hours (IFN-g ELISpot) or
4 hours (GrB ELISpot), plates were developed and the mean number of spots
per duplicate well was calculated.Statistics
Statistical analyses were performed using GraphPad Prism v5.02 soft-
ware (San Diego, California, USA). Levels of signiﬁcance were calculated by
Mann-Whitney rank-sum test, expressed as P values (*P < .05, yP < .01,
zP< .001), and displayed graphically as mean SD as speciﬁed in the ﬁgures.
To standardize the results for the calculation of the normalized (n)spw50
value in the titration experiment (Supplementary Figure S-F2 B), we
normalized the set of data obtained for the different peptide pools by
mapping the original data range in a uniform scale of 0 to 100% normalized
number of spw using GRAPHPAD PRISM V5.02 software.Figure 1. Detection of CMV-speciﬁc T Cells by IFN-g ELISpot. Frequency of CMV-speci
peptide pools. Peripheral blood mononuclear cells (PBMCs) from 204 donors were isol
control), stimulated with .6 nmoL of each peptide/mL peptide pool, and incubated ove
virus control peptide pool (CEF pool) served as positive controls. Asterisks indicate st
(*P < .05, yP < .01, zP < .001). (A) All 204 donors were tested for anti-CMV IgG antibodie
(CMVe). CMV-seropositive donors were grouped according to the number of spots
responders (HR) (50 spw), low responders (LR) (10 to 50 spw), and nonresponders (N
overall responder group. After conﬁrmatory serological testing by Western blot ana
number of actual nonresponders decreased to 0 (0C) for pp65 and to 26 (26C) for I
n ¼ 124) in the overall group and responder groups; the results of independent expe
donor to both peptide pools in comparison, ie, the numbers of pp65-high, low, and no
induced more cytokine secretion in all but 1 donor, who showed a high response to
identiﬁed by ELISpot among the 17 HLA-A*02:01þ/CMV-seropositive donors who remRESULTS
CMV-speciﬁc T Cells are Readily Induced and More
Frequently Directed against pp65
To assess the responsiveness of T cells against different
peptide pools derived from CMV proteins, IFN-g secretion by
T cells from 204 healthy donors in response to ppCMVpp65
and ppCMVIE-1 was determined by ELISpot (Figure 1).
All donors were pretested for anti-CMV IgG antibodies by
ELISA. According to these ﬁrst serology results, 143 (71%) of
the enrolled donors were considered CMV-seropositive and
61 (29%) were CMV-seronegative. None of the samples of
CMV-seronegative donors yielded positive ELISpot results.
Surprisingly, in a ﬁrst analysis, we found 19 samples from the
seropositive group (Figure 1A) that did not react to neither
pp65 nor IE-1. To validate the ELISpot and exclude false-
positive ELISA results for CMV-serostatus, we repeated
serology testing in backup samples usingWestern blot. Thus,
the 19 nonresponders in ELISpot were identiﬁed as CMV-
seronegative, resulting in a false-positive rate of 13% in the
ﬁrst serology testing. Ultimately, 124 of 204 donors (61%)ﬁc T cells detected by IFN-g secretion after stimulation with CMVpp65 and IE-1
ated, suspended at a density of 2.5  105 cells in 1 mL culture medium (negative
r night. PBMCs stimulated with 10 mg/mL cytomegalovirus, Epstein-Barr, and ﬂu
atistically signiﬁcant differences between levels of induced cytokine responses
s by ELISA. 143 were CMV-seropositive (CMVþ) and 61 were CMV-seronegative
per well (spw) generated in response to each peptide pool as follows: high
R) (10 spw); high responders and low responders were summed to yield the
lysis, the number of CMV-seronegative donors increased to 80 (80C) and the
E-1. (B) Differentiation between conﬁrmed CMV-seropositive donors (CMVþ,
riments are expressed as mean number of spw  SD. (C) The response of each
nresponders among each of the IE-1 responder groups. The pp65 peptide pool
IE-1 but only a low response to pp65. (D) Frequencies of pool-speciﬁc T cells
ained negative in the ﬂow cytometric analysis using the mA02-pp65.
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CMV-seronegative.
Considering the results of the conﬁrmatory serological
testing (Figure 1A), we found that all CMV-seropositive
donors exhibited a positive response to ppCMVpp65,
whereas only 79% (n ¼ 98) responded to ppCMVIE-1.
Among the CMV-seropositive donors were 106 (85%) pp65
and 54 (43%) IE-1 high responders, 18 (15%) pp65, and 44
(35%) IE-1 low responders, and, remarkably, no pp65
nonresponders, but 26 (21%) IE-1 nonresponders. Results
also showed that overall mean reactivity to ppCMVpp65
(164.4  118.9) was signiﬁcantly higher than to ppCMVIE-1
(73.0  92.3; P < .001) (Figure 1B). With only 1 exception,
all ppCMVIE-1 high responders were also pp65 high
responders (Figure 1C). Yet, among the 106 ppCMVpp65
high responders were only 53 (50%) ppCMVIE-1 high
responders, in addition to 38 (36%) IE-1 low responders and
15 (14%) IE-1 nonresponders.
CMV-speciﬁc T cells were also identiﬁed by mA02-pp65
pentamer staining on PBMCs from HLA-A*02:01-positive
donors (n ¼ 127, 78 CMV-seropositive, representative plots
in Supplementary Figure S-F1). As anticipated, the pentamer
did not stain cells from the 49 seronegative donors. Among
the CMV-seropositive donors, a distinct pentamerþ/CD8þ
population was detectable in 61 donors (78%; mean, 1.41%;
range, .24% to 13.55%). Recently, it was shown that in indi-
viduals sharing HLA-A*02:01 and B*07:02, the B*07:02
response prevailed [38]. The response against the HLA-
A*02:01 epitope was signiﬁcantly lower than in individuals
not expressing B*07:02. Analysis of the HLA-distribution for
mA02-pp65-negative donors conﬁrmed that the expression
of HLA-B*07:02 is associated with a decreased frequency of
mA02-pp65especiﬁc T cells (Supplementary Figure S-F3).
The frequency of pp65495-504especiﬁc CD8þ T cells was
signiﬁcantly higher in HLA-A*02-positive HLA-B*07-negative
donors (mean, 1.78%) compared with n HLA-A*02-positive
HLA-B*07-positive donors (mean, .68%; P ¼ .011). This is in
concordance with the ﬁndings in patients after HSCT, where
coexpression of B07 was found to be associated with signif-
icantly lower levels of A02-CMV-CTL [39]. In addition, in our
cohort, we found the ﬁrst evidence that the expression of
HLA-A*03 and HLA-B*13 also seem to have a negative impact
on mA02-pp65especiﬁc T cells, whereas expression of HLA-
A*24, -A*26, -A*33, -B*14, -B*15, -B*18, -B*40, and -B*51 did
not inﬂuence the response to the A02-pp65 epitope.
Despite mA02-pp65-negativity, in ELISpot assay
ppCMVpp65 (mean, 153.4 spw) caused higher cytokine
secretion than ppCMVIE-1 (62.9 spw) in all cases but 1, in
which spot counts were equal (Figure 1D). ppCMVpp65 high
responders accounted for 82% of the HLA-A*02:01þ/mA02-
pp65-negative donors.
Thus, responses to ppCMVpp65 could be detected in every
single CMV-seropositive donor and were signiﬁcantly
stronger than responses to ppCMVIE-1, to which only 79% of
donors responded. The mA02-pp65 pentamerebound CD8þ
T cells in 78% HLA-A*02:01-positive donors. Of 143, 19 (13%)
donors were tested false-positive for CMV antibodies by
routine serology.
Lymphocytes Directed against EBV Respond Highest to
BZLF1
As expected, EBV-seronegative donors (n ¼ 9) showed no
speciﬁc Tcells in response to any of the 3 EBV-derived peptide
pools. T cells against the ppEBVBZLF1 were most frequent
amongEBV-seropositive donors (n¼ 195, Figure 2A), as shownby the highest number of total (n ¼ 112, 57%) and high
responders (n¼ 56, 29%), in contrast to 90 (49%) and 24 (12%)
responders for ppEBVEBNA-1, and 64 (33%) and 14 (7%)
responders forppEBVLMP2A, respectively. Figure2B illustrates
the response of each EBV-seropositive donor to the different
pools in comparison. Although 35 donors (18%) responded
positively to all 3 EBV peptide pools, 53 donors (27%) did not
react to any of these, despite seropositivity. A total of 35 (18%),
10 (5%) and6 (3%) donors reacted to ppEBVBZLF1, ppEBVEBNA-
1, and ppEBVLMP2 A only, respectively. Conversely, 12 (6%)
donors were negative only to ppEBVBZLF1, 11 (6%) only to
ppEBVEBNA-1, and 33 (17%) to ppEBVLMP2 A. Though immune
responses to all 3 peptide mixtures were lower than those to
CMV peptide pools, data from all EBV-positive donors
demonstrate signiﬁcantly higher cytokine-secreting cells for
ppEBVBZLF1 (41.2  57.6 spw) than for ppEBVEBNA-1
(21.5 34.1 spw, P¼ .004) andppEBVLMP2A, (14.8 28.2 spw,
P < .001), respectively (Figure 2C).
EBV-speciﬁc T lymphocytes were directly visualized using
the HLA-restricted pentamers mB08-BZLF1, mB08-EBNA-3A,
andmB35-EBNA-1 (Supplementary Figure S-F1). As 35 of 204
donorswereHLA-B*08:01 typed (34 EBV-seropositive,1 EBV-
seronegative), this provided the possibility to compare
frequencies of T cells directed against BZLF1 and EBNA-3A.
Among seropositive donors, a higher number showed
speciﬁc cells against BZLF1 (31 of 34donors, 91%) than against
EBNA-3A (24 of 34 donors, 71%). Overall, pentamerþ/CD8þ
cell counts were also signiﬁcantly higher for mB08-BZLF1
(mean, 1.58%; range, .21% to 5.16%) than for mB08-EBNA-3A
(.48%; range, .13% to 3.16%; P < .001). All BZLF1-negative
donors were also negative for EBNA-3A. mB35-EBNA-1
bound .14% to 1.80% (mean, .60%) of CD8þ T cells in 11 of 21
(52%) HLA-B*35:01þ EBV-seropositive donors.
Low-memory T Cell Frequencies Detectable for Human
Adenovirus
A hexon derived peptide pool (ppADV5hexon) was used
for the detection of adenovirus-speciﬁc T cells. Using the
alphaWell Adenovirus ELISA, no ADV-speciﬁc antibodies
were detected in 8 out of 204 donors (ADV-seronegative, 4%).
In the ADV-seropositive subpopulation (n ¼ 196, 96%)
response was classiﬁed as follows (Figure 3A): 144 (73%)
responders, consisting of 59 high responders (30%), 85 low
responders (43%), and 52 nonresponders (27%). Overall, the
mean frequency of ADV-speciﬁc T cells was 41.6  49.0 spw
(Figure 3B). As expected, the 8 ADV-seronegative donors did
not respond.
ADV-speciﬁc T cell rates determined by ﬂow cytometry
were strikingly low for all 3 pentamers (Supplementary
Figure S-F1). Ten of 58 (17%) donors stained positive for
mA01-Hex (mean, .54%; range, .08% to 1.47%), 7 of 35 (20%)
for mA24-Hex (mean, .37%; range, .14% to .52%), and 8 of 63
(13%) for mB07-Hex (mean, .43%; range, .31% to .63%). No
pentamer-positive cells were detected in any of the donors
classiﬁed as ADV-seronegative.
Low-frequency Memory T Cells Are Hard to Detect
without Antigen Stimulation
PBMCs (n ¼ 30 donors) were stimulated for 7 days with
the respective HLA-matched viral peptide to investigate
whether individuals with a potential low-frequency
response not detectable by multimer staining on day 0 did,
in fact, belong to the nonresponder group (Table 1,
Supplementary Figure S-F4). In each experimental setting,
seronegative donors were used as controls.
Figure 2. Frequencies of antigen-speciﬁc T cells against different EBV-derived peptide pools. Detection of EBV-speciﬁc T cells in 204 donors by antigen-induced IFN-g
secretion in ELISpot after stimulation with 3 different peptide pools: EBNA-1, LMP2 A and BZLF1. (A) Donors were tested by Western blot for anti-EBV IgG antibodies
(195 EBV-seropositive, EBVþ; 9 EBV-seronegative, EBV). Seropositive donors were divided into responder groups for each peptide pool according to the frequency of
generated spots per well (spw) as follows: high responders (HR) (50 spw), low responders (LR) (10 to 50 spw), nonresponders (NR) (10 spw) and “responders”
(total of HR and LR). (B) Distribution of positive (þ) and negative () T cell responses against the 3 different EBV-speciﬁc peptide pools among EBV-seropositive
donors (n ¼ 195). (C) Differentiation between EBV-seropositive donors (EBVþ, n ¼ 195) in the overall and individual responder groups. Results of independent
experiments are expressed as the mean number of spw  SD. Asterisks indicate statistically signiﬁcant differences between levels of induced cytokine responses
(*P < .05, yP < .01, zP < .001).
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Thirteen conﬁrmed HLA-A*02:01þ/CMV-seropositive
donors, all of whom responded to ppCMVpp65, were stimu-
lated with pA02-pp65. Cells from 9 of the 13 (69%) donors
were tested positive by both pentamer staining and peptide
ELISpot before and after 7 days of stimulation (Supplementary
Figure S-F4 A). Additionally, during pA02-pp65especiﬁc
stimulation, the frequency of mA02-pp65þ/CD8þ T cells, as
well as the mean spot count, signiﬁcantly increased (day 0:
.75%, 83.1 spw; day 7: 8.10%, 180.2 spw). In 4 of the 13 (31%)
donors, no response to pA02-pp65 was determined on days
0 and 7, giving strong evidence that, in these donors, no
memory T cells against pA02-pp65 were present. Eight
ppCMVpp65þ/CMVeseropositive donors were stimulated
with pA01-pp65 and speciﬁc T cells were observed in 5 (63%)
of these donors on days 0 and 7 in both assays.EBV
All donors tested (n ¼ 8) responded to the B08-BZLF1
epitope on day 0, indicating that this epitope is strongly
immunodominant. After pB08-BZLF1especiﬁc stimulation,
a strong increase in the pentamerþ cell frequency as well as
in the IFN-g secretionwas observed (day 0: 1.20%, 140.9 spw;
day 7: 10.72%,155 spw). Interestingly, pentamer-negative but
IFN-g-positive (A02-LMP2: n ¼ 4, 25%), as well as pentamer-
and IFN-g-negative donors (A02-LMP2: n ¼ 3, 19%), turned
positive in both assays after peptide-speciﬁc stimulation
(Supplementary Figure S-F4 B). Nevertheless, for A02-LMP2,
B08-EBNA-3A, and B35-EBNA-1, no speciﬁc T cells could be
induced in 7 (43%), 1 (12.5%), and 2 (40%) of the donors,
respectively. As nearly one half of all donors tested did not
react to A02-LMP2 (43%) or B35-EBNA-1 (40%), these
epitopes seemed less immunodominant.
Figure 3. Detection of ADV hexon pool-speciﬁc T cells by IFN-g ELISpot. (A)
Donors were screened for anti-ADV IgG antibodies by ELISA (196 ADV-
seropositive, ADVþ; 9 ADV-seronegative, ADV). Seropositive donors were
divided into responder groups according to the number of generated spots per
well (spw) as follows: high responders (HR) (50 spw), low responders (LR):
(<50 and >10 spw; n ¼ 85), nonresponder (NR) 10 spw), and “responders”
(total of HR and LR). (B) Classiﬁcation of responder groups for the ADV5 hexon
pool as determined for ADV-seropositive donors (ADVþ, n ¼ 196). Results of
independent experiments are expressed as the mean number of spw  SD.
Asterisks indicate statistically signiﬁcant differences between levels of induced
cytokine responses (*P < .05, yP < .01, zP < .001).
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So far, for CMV and EBV, we identiﬁed seropositive
donors, which were pentamerþ/IFN-gþ, pentamer-/IFN-g-,
and pentamer-/IFN-gþ on day 0. Interestingly, for ADV, we
also identiﬁed pentamerþ/IFN-g- donors. As expected, these
donors became positive in ELISpot assay after 7 days of
peptide-speciﬁc stimulation. The number of pentamerþ/IFN-
gþ donors on day 0 was low (4 of 16, 25%, A01-Hex,
Supplementary Figure S-F4 C; 1 of 6, 17%, A24-Hex; 4 of 14,
29%, B07-Hex). However, after 7 days of stimulation, ADV-
speciﬁc T cells were detected in nearly 60% to 70% of
donors (11 of 16, 69%, A01-Hex; 4 of 6, 67%, A24-Hex; 8 of 14,
57%, B07-Hex).
Taken together, both methods employeddELISpot and
pentamer stainingdare suitable to identify donors with
a revocable response against the various viruses. In
multimer-negative but ELISpot-positive donors, a T cell
response detectable with both methods could be induced by
restimulation with the respective viral epitopes.
Detection of Antiviral Memory T Cells by ELISpot Assay
Correlates with the IFN-g Secreting Cells Detected by
Cytokine Secretion Assay
Antiviral T cells for clinical use can be isolated by antigen-
triggered secretion of cytokines after short in vitro stimula-
tion [25]. We evaluated whether the detection of memory
T cells by IFN-g ELISpot assay correlates with the detection of
IFN-g-secreting cells after stimulation with ppCMVpp65,
ppEBVBZLF1, ppADV5hexon, ppCMVIE-1, ppEBVEBNA-1,
and/or ppEBVLMP2 A (Figure 4, Table 2, SupplementaryTable S-T2). For all donors, T cell responses were detectable
by ELISpot assays and CD8þ, as well as CD4þ IFN-g-secreting
cells ppADV5hexon, in the majority of donors (3 of 4)
a slightly stronger CD4þ T cell response could be detected.
For all other antigens used, most donors showed higher
frequencies of CD8þ IFN-g-secreting cells (Figure 4, Table 2,
Supplementary Table S-T2).Cytotoxic T Lymphocytes Detected by Flow Cytometry and
ELISpot Show High Speciﬁcity
Expanded cells from HLA-A*02:01þ/CMV-seropositive
donors were tested after pA02-pp65 stimulation against irra-
diated pA02-pp65-loaded and unloaded autologous PBMCs as
well as loaded and unloaded allogeneic PBMCs by IFN-g and
GrB ELISpot after enumeration of mA02-pp65þ/CD8þ cells via
FACS analysis (Table 3). Donors were divided into group A
through C (A: A*02:01þ/CMV-seropositive, B: A*02:01þ/CMV-
seronegative, C: A*02:01-/CMV-seropositive donors). In both
assays, spot counts were higher in cases where target PBMCs
presented pA02-pp65 (groups A and B) and in donors with
considerable amounts of speciﬁc effector CTLs (donors 1 and
2), indicating targeted cytotoxic CTL activity. In contrast, no or
low cytokine expressionwas observedwhen unloaded PBMCs
and PBMCs from HLA*02:01-donors (group C) were used as
targets, and effector cells from donors who did not respond to
pA02-pp65 showed no considerable secretion of IFN-g and
GrB (donor 3), implying absence of speciﬁc CTL activation, as
well as alloreactivity in both scenarios.
In general, the more sensitive and more speciﬁc GrB
ELISpot detected more spw with regard to peptide-loaded
target cells and fewer spots per well for combinations in
which no cytotoxic activity was expected (eg, unloaded or
HLA-A*02:01- targets). As proof of principle, this assay was
validated to assess speciﬁcity and exclude alloreactivity of
puriﬁed HLA-A*02:01-restricted pp65-reactive T cells, as this
is a known immunodominant target elucidating a strong
cytotoxic response. We are currently validating this assay
with respect to those targets, which are known to be less
immunodominant (eg, ADV5 hexon epitopes). To deﬁne
a cut-off for alloreactive cells, in vivo data are necessary.
Therefore, clinical data after adoptive transfer with respect to
the HLA-types, the antigens used, and the amount of
antigen-speciﬁc and nonspeciﬁc cells have to be correlated
with the results obtained in this assay. However, to ensure
patient safety, all nonvirus-speciﬁc T cells should be
considered alloreactive and, thus, the dose should be below
2.5  104/kg patient body weight in a haploidentical trans-
plantation setting to avoid infusion-induced GVHD.T Cell Frequencies Are Constant throughout Multiple
Donations
PBMCs of 54 donors from multiple donations (mean, 3;
range, 2 to 6) were tested against peptide pools in ELISpot
assays and stained with speciﬁc pentamers according to the
respective donor’s HLA-type. Table 4 shows representative
ELISpot data for 4 individuals who donated cells at 3 different
times, with a mean of 99  47 days between the ﬁrst and
second donation and a mean of 155  46 days between ﬁrst
and last donation. All data from multiple donations showed
consistent results of ELISpot (responder or nonresponder
status for a certain peptide pool) and pentamer staining
(positivity or negativity for a speciﬁc pentamer, data not
shown), with no signiﬁcant differences between the results
obtained at different time points.
Table 1

















A02-pp65 (total n ¼ 13) þ/þ/ þ/þ 9 (69%) Pos (83.1) Pos (.75) Pos (180.2) Pos (8.10)
// / 4 (31%) Neg (2.9) Neg (.03) Neg (2.75) Neg (.04)
A01-pp65 (total n ¼ 8) þ/þ/ þ/þ 5 (63%) Pos (43.3) Pos (.51) Pos (123.7) Pos (6.77)
/// 3 (37%) Neg (5.7) Neg (.06) Neg (6.3) Neg (.13)
EBV
A02-LMP2 (total n ¼ 16) þ/þ/ þ/þ 2 (13%) Pos (18.8) Pos (.22) Pos (344.8) Pos (1.81)
þ/-/ þ/þ 4 (25%) Pos (40.6) Neg (.09) Pos (273.8) Pos (3.91)
// þ/þ 3 (19%) Neg (3.7) Neg (.05) Pos (266.8) Pos (2.06)
// -/- 7 (43%) Neg (4.5) Neg (.03) Neg (2.3) Neg (.06)
B08-BZLF1 (total n ¼ 8) þ/þ/ þ/þ 8 (100%) Pos (140.9) Pos (1.20) Pos (155.0) Pos (10.72)
B08-EBNA-3A (total n ¼ 8) þ/þ/ þ/þ 7 (87.5%) Pos (70.9) Pos (.49) Pos (111.1) Pos (2.93)
// / 1 (12.5%) Neg (.0) Neg (.01) Neg (3.0) Neg (.05)
B35-EBNA-1 (total n ¼ 5) þ/þ/ þ/þ 3 (60%) Pos (117.2) Pos (.89) Pos (200.8) Pos (6.91)
// / 2 (40%) Neg (1.5) Neg (.21) Neg (4.5) Neg (.16)
ADV
A01-Hex (n ¼ 16) þ/þ/ þ/þ 4 (25%) Pos (49.8) Pos (.93) Pos (116.9) Pos (5.75)
þ/-/ þ/þ 2 (12.5%) Pos (36.3) Neg (.23) Pos (145.8 Pos (3.28)
/þ/ þ/þ 2 (12.5%) Neg (3.3) Pos (.98) Pos (28.0) Pos (1.07)
// þ/þ 3 (19%) Neg (2.8) Neg (.09) Pos (68.7) Pos (2.23)
// / 5 (31%) Neg (2.8) Neg (.23) Neg (2.7) Neg (.20)
A24-Hex (n ¼ 6) þ/þ/ þ/þ 1 (17%) Pos (30.5) Pos (.24) Pos (55.5) Pos (1.07)
/þ/ þ/þ 1 (17%) Neg (3.5) Pos (.16) Pos (124.0) Pos (5.45)
// þ/þ 2 (33%) Neg (4.3) Neg (.16) Pos (105.3) Pos (3.44)
// / 2 (33%) Neg (3.3) Neg (.13) Neg (.5) Neg (.12)
B07-Hex (n ¼ 14) þ/þ/ þ/þ 4 (29%) Pos (76.0) Pos (.60) Pos (102.8) Pos (4.27)
/þ/ þ/þ 3 (21%) Neg (4.0) Pos (.57) Pos (20.50) Pos (1.22)
// þ/þ 1 (7%) Neg (7.0) Neg (.01) Pos (16.0) Pos (.10)
// / 6 (43%) Neg (1.5) Neg (.08) Neg (3.4) Neg (.19)
PP indicates peptide pool; ELISpot, enzyme-linked immunospot; CMV, cytomegalovirus; EBV, Epstein-Barr virus; ADV, adenovirus; spw, spots per well.
All observed constellations of matched pentamer and ELISpot analyses after peptide stimulation are shown. Stimulation of antiviral T cells was performed using
isolated peripheral blood mononuclear cells (PMBCs) from a total of 30 donors. With regard to the donors’ HLA types, virus-speciﬁc T cell frequencies in virus-
seropositive donors were determined before stimulation (day 0) by pentamer staining (mean %) and in IFN-g ELISpot (peptide, mean spots per well [spw]) using
the respective matched peptides: CMV: A*02:01/NLVPMVATV (A02-pp65, n ¼ 13) and A*01:01/YSEHPTFTSQY (A01-pp65, n ¼ 8); EBV: A*02:01/CLGGLLTMV
(A02-LMP2, n ¼ 16), B*08:01/RAKFKQLL (pB08-BZLF1, n ¼ 8), B*08:01/FLRGRAYGL (B08-EBNA-3A, n ¼ 8), and B*35:01/HPVGEADYFEY (B*35-EBNA-1, n ¼ 5);
ADV: A*01:01/TDLGQNLLY (A01-Hex, n ¼ 16), A*24:02/TYFSLNNKF (A24-Hex, n ¼ 6), and B*07:02/KPYSGTAYNAL (B07-Hex, n ¼ 14). After 7 days of in vitro
stimulation with the respective peptides, cells were harvested and analyzed by pentamer staining (mean %) and IFN-g ELISpot (peptide, mean spw). The mean
number of spw (mean spw) and the percentage of CD8þ/pentamerþ cells (mean %) were calculated for the respective used peptides. For example, 9 of 13 (69%)
donors were tested positive by both pentamer staining and peptide ELISpot before (day 0) and after 7 days of stimulation. During pA02-pp65especiﬁc stim-
ulation, the frequency of mA02-pp65þ/CD8þ T cells, as well as the mean spot count, signiﬁcantly increased (day 0: .75%, 83.1 spw; day 7: 8.10%, 180.2 spw;
P < .001, respectively). For the other 4 of 13 donors (31%), no T cell response was detected by both methods and both points of time.
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Thawed PBMCs
Cryopreserved aliquots of donor samples (n ¼ 17) were
retested by ELISpot and pentamer staining after intervals of
4 weeks, 3 months, and 6 months. Donors were divided into
3 responder groups (high responders, low responders,
nonresponders) by the results obtained in IFN-g ELISpot and
using freshly isolated PBMCs. All donors who tested positive
to a given peptide pool maintained this responder status
after the subsequent thawing procedures (Figure 5). No
signiﬁcant variation between the means obtained with fresh
versus frozen PBMCs in any of the responder groups or
peptide pools was observed. Accordingly, all donors
remained positive (or negative) for the respective pentamer
when the tests were repeated in frozen samples thawed at
different time points (data not shown).
DISCUSSION
Adoptive immunotherapy with virus-speciﬁc effector T
cells can safely and efﬁciently prevent post-transplantation
infections by common viruses such as CMV, EBV, or ADV in
immunosuppressed patients. The development of GMP-grade
T cell isolation systems, based on IFN-g secretion and T cellreceptor staining, facilitates isolationof clinical-gradeantiviral
T cells without the need for stringent manipulation of cells by
time- and labor-consuming in vitro expansion procedures.
Nevertheless, these technologies require the presence of
virus-speciﬁc memory T cells in the respective donors. This
study focused on 3 key aspects of the advancement of T cell
donor selection in this ﬁeld: (1) application and validation of
a high-throughput assay to screendonors for their virus status
and to monitor them for their individual virus-speciﬁc
memory T cell repertoires, (2) identiﬁcation of the most
immunodominant virus-speciﬁc target antigens capable of
generating clinically useful Tcells, and (3) establishment of an
expedient in vitro assay for the determination of T cell
alloreactivity.
Using virus-speciﬁc peptide pools, at least 124 (61%)
potential CTL donors were identiﬁed for each virus. All 124
CMV-seropositive donors reacted to ppCMVpp65. Of EBV-
seropositive donors, 73% had antigen-speciﬁc T cells to at
least 1 of 3 EBV pools, with the highest frequency for
ppEBVBZLF1. Of 196 ADV-seropositive donors, 144 reacted
against ppADV5hexon. To identify low-frequency antiviral T
cells, short in vitro stimulations were performed, revealing
that some donors who were negative for certain ADV and/or
Figure 4. Antiviral T cells detected by IFN-g cytokine secretion assay and ELISpot. Representative ELISpot data and results of IFN-g cytokine secretion assay for 2
representative donors. Fresh peripheral blood mononuclear cells were stimulated with ppCMVpp65, ppADV5hexon and ppEBVBZLF1, and secretion of IFN-g was
determined by ELISpot and cytokine secretion assay. Cells stimulated with 10 mg/mL cytomegalovirus, Epstein-Barr virus, and ﬂu virus control peptide pool (CEF pool)
served as positive controls, cells suspended in 1 mL culture medium as negative controls.
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peptide stimulation. In contrast, stimulation with CMV
peptides did not alter an initially negative result.
Importance of Serological Testing in the Transplant
Setting and Correlation with Occurrence of Memory
T Cells
Donor seropositivity provides an opportunity to transfer
virus-speciﬁc lymphocytes to mediate immune protection in
the immunosuppressed recipient [40,41]. Correlating theTable 2
Antiviral T Cells Detected by IFN-G Cytokine Secretion Assay and ELISpot












Donor 1 296 0 227 30 12 2.38 1.51
Donor 2 276 0 145 45 38 2.87 1.76
Donor 3 260 1 298 74 122 .93 3.10
Donor 4 160 1 234 214 28 .87 1.08
ELISpot indicates enzyme-linked immunospot; PC, positive control; NC, negative co
adenovirus.
Representative ELISpot data and results of IFN-g cytokine secretion assay for 4 don
ppADV5hexon and ppEBVBZLF1, respectively and secretion of IFN-g was determin
cytomegalovirus, Epstein-Barr virus, and ﬂu virus control peptide pool (CEF pool) se
negative control.
* The values represent the percent of CD3, CD4, or CD8 T cells that are positiveresults from routine ELISA-based serology to antigen-speciﬁc
T cell responses to CMV peptide pools using IFN-g ELISpot
assay, we found 19 out of 143 (13%) initially serologically
positive donors did not mount an immune response against
CMV-speciﬁc peptide pools. Western blot analyses yielded
negative results, indicating that the initial ELISA results for
these donors may have been false-positive. Because it is well
accepted that, at least in CMV-infected persons, the CTL,
as well as the antibody production, is dependent on rein-
















.86 .23 .13 .10 .26 .14 .12
1.08 1.21 .65 .55 .97 .44 .52
.31 1.09 .50 .58 2.88 1.81 3.29
.58 1.56 1.44 1.52 .69 .51 .96
ntrol; pp, peptide pool; CMV, cytomegalovirus; EBV, Epstein-Barr virus; ADV,
ors. Peripheral blood mononuclear cells were stimulated with ppCMVpp65,
ed by ELISpot and cytokine secretion assay. Cells stimulated with 10 mg/mL






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































C. Sukdolak et al. / Biol Blood Marrow Transplant 19 (2013) 1480e14921488primarily infected with CMV a long time ago, without recall
immunization.
After initial Western blot assays to determine the donors’
serological status for EBV, we retrospectively tested the
donors’ plasma for anti-EBV IgG antibodies by ELISA,
(Enzygnost anti-EBV-IgG, Dade Behring, Newark, Denmark,
data not shown). This was done to evaluate whether
detection of anti-EBV IgG antibodies by ELISA also gives
false-positive results as observed for CMV. We found that 2
donors negative in recomBlot and without a detectable EBV-
speciﬁc T cell response in the ELISpot assay were (false-)
positive in ELISA. Unfortunately, for EBV, none of the avail-
able peptide pools is as immunodominant as ppCMVpp65
(all CMV-seropositive donors gave ppCMVpp65-positive
response in ELISpot). Therefore, absence of an EBV-speciﬁc
T cell response does not clearly correlate with seronega-
tivity and, as our data show, false serostatus is also not the
explanation for absent responses to ppEBVBZLF1, ppEB-
VEBNA-1, and ppEBVLMP2 A in some donors. However,
because in our study the recomBlot results were used to
determine the EBV-serostatus and these donors were
initially classiﬁed as seronegative and did not give T cell
responses speciﬁc for EBV, the described results were not
inﬂuenced.
By analyzing the reactivity to a single CMV peptide
epitope, we found 22% HLA-A*02:01þ/CMV-seropositive
donors for whom no pentamerþ/CD8þ population was
detectable. All of these donors were categorized as either
ppCMVpp65-high or low responders (Figure 1A-B). It is
likely that reactivity to ppCMVpp65 was mediated by
a different HLA-allele than the well-characterized HLA-
A*02:01 epitope. Therefore, the distribution of HLA alleles
in mA02-pp65-negative donors was analyzed. We found
a strong negative correlation with the expression of HLA-
B*07 as well as with B*13 and HLA-A*03 (Supplementary
Figure S-F3). It is known that the B*07:02 response is pre-
vailed in individuals sharing HLA-A*02:01 and B*07:02
[38]. Accordingly, a higher frequency of HLA-B*07-than
HLA-A*02-restricted CMV-speciﬁc T cells was observed
also in the donors in the study of Schmitt et al. (B*07 .57%
versus A*02 .05%) [23].
The results emphasize that with regard to donor selection
and the outcome of adoptive immunotherapy and HSCT in
general, standard serology tests alone might not be the only
reliable analytical method, and that no peptide-speciﬁc
memory T cells might be present despite seropositivity
[42]. Recently, Loeth et al. [41] found CD4 and/or CD8 pp65-
speciﬁc T cell responses in 5 out of 44 seronegative individ-
uals. This number was increased to 34 (77%) after 7 days of
in vitro stimulation. Thus, screening stem cell donors and
potential T cell donors to establish whether a donor is
capable of initiating a T cell response against a speciﬁc virus
might improve outcome of HSCT, at least for virus reac-
tivation and treatment options.
Immunodominant Epitopes Are Essential to Isolate
Clinical-grade T Cells at High Purities
Published study results are promising, demonstrating
comparable safety of T cell infusions and excellent toxicity
proﬁles for both reversible pMHC streptamer technology
and the cytokine capture technology [6-8,10-12,14,23,43].
Knowledge of immunodominant viral target epitopes is
essential to isolate pure, highly speciﬁc, and effective T cells
and thereby minimize the risk of inducing GVHD. The IFN-g
ELISpot assay was recently identiﬁed as the most eligible
Table 4
Peptide PooleSpeciﬁc T Cells Detected by IFN-G ELISpot during Multiple Donations
Spots per Well (spw) after Stimulation with Peptide Pools (2.5  105 PBMCs/Well)
ppCMVpp65 ppCMVIE-1 ppADV5hexon ppEBVEBNA-1 ppEBVLMP2 A ppEBVBZLF1
Donor 1
Donation 1 0 0 6.5 24 34 .5
Donation 2 0 1 5 32 61 7
Donation 3 0 0 5 22 37 1.5
Mean  SD 0  0 .3  .5 5.5  .7 26.0  4.3 44  12.1 3.0  2.9
Donor 2
Donation 1 5 7 82 2.5 5 3
Donation 2 .5 0 54 1 0 0
Donation 3 1.5 1 52 .5 .5 2
Mean  SD 2.3  1.9 2.67  3.1 62.7  13.7 1.3  .8 1.8  2.2 1.7  1.2
Donor 3
Donation 1 103.5 37 8.5 3.5 0 49
Donation 2 101 15 1 5.5 0 48.5
Donation 3 91 16.5 7 5 1 41
Mean  SD 98.5  5.4 22.8  10.0 5.5  3.2 5.5  .8 .3  .5 46.1  3.7
Donor 4
Donation 1 198 60 35 0 1 2
Donation 2 152.5 25 19 1.5 2 7
Donation 3 157 36 16 5 0 7
Mean  SD 169.2  20.5 40.3  14.6 23.3  8.3 2.17  2.1 1.0  .8 5.3  2.4
Representative ELISpot data for 4 individuals who donated cells at 3 different times, with a mean of 99  47 days between the ﬁrst and second donation and
a mean of 155 46 days between the ﬁrst and last donation. 2.5 105 cells suspended in 1 mL culture medium (negative control) were stimulated with 1 mg per
peptide/mL peptide pool (ppCMVpp65, ppCMVIE-1, ppEBVEBNA-1, ppEBVLMP2A, ppEBVBZLF1, ppADV5hexon) and incubated over night. Peripheral blood
mononuclear cells stimulated with 10 mg/mL cytomegalovirus, Epstein-Barr, and ﬂu virus control peptide pool (CEF pool) served as positive controls.
C. Sukdolak et al. / Biol Blood Marrow Transplant 19 (2013) 1480e1492 1489method for high-throughput screening to monitor antigen-
speciﬁc T cell immunity in potential T cell donors by prior
investigation of our group (Tischer, Dieks et al., submitted).
The IFN-g ELISpot assay is a simple, fast, and cost-effective
technique that allows the parallel analysis of numerous
donors for their responses to a large set of different antigens
at the same time, and we now conﬁrmed its feasibility con-
cerning the use of frozen donor material and proved the
consistency of the observed T cell frequencies over time. This
enables to retest thawed PBMCs with newly discovered
epitopes and supports to rely on prescreened donors with
known frequencies in case of urgently needed donation.
The antigens used in our study were all derived from
proteins that were shown to be immunodominant [33,36,37]
but they were never investigated on such a large scale
screening of healthy donors. Our data show that CMV-speciﬁc
T cells are readily induced and detected by peptides derived
from pp65 or IE-1. They also support previous ﬁndings that
pp65 is themore immunodominant protein that causesmore
frequent and stronger T cell responses [33,44]. For EBV, weFigure 5. High-responder ELISpot data for fresh and frozen peripheral blood monon
ELISpot data sets for 17 healthy donors were divided as follows into 3 responder gr
stimulation of fresh PBMCs: high responders (HR) (50 spw), low responders (LR)
cryopreserved and retested after thawing the samples 4 weeks (4wk) and 3 months (3
responders by ELISpot with fresh PBMCs (CMVpp65: n ¼ 9; CMV IE-1: n ¼ 8; ADV5 hex
expressed as mean  SD. There was no variation of the means determined with fresh
peptide pools (*P > .05).were able to demonstrate that peptides, especially from
BZLF1 but also EBNA-1 and -3, are potent T cell stimulators
occurring at high frequencies in healthy individuals.
Hexon, the major capsid protein of ADV, was previously
proven to be immunodominant and conserved among
different ADV serotypes and also shown to be a more
pronounced T cell target antigen than the other major capsid
proteins, penton base and ﬁber [14,37,45-47]. However, in
our study, as well as in the study of Geyeregger et al. (2013),
frequencies of speciﬁc CD8þ effector T cells against the
previously identiﬁed hexon-derived HLA-restricted peptides
remained markedly low and often undetectable without
in vitro stimulation [48]. In 3 of 4 donors, we found that the
response to the hexon-derived epitopes was mainly
restricted to CD4þ T cells. Taken together, our data regarding
ADV-speciﬁc T cell responses may imply the relevance of
other immunogenic proteins and emphasizes the need for
further investigation in epitope mapping.
In the future, we will extend typing and proﬁling of poten-
tial third-party donors to include the Tcell frequencies of otheruclear cells (PBMCs) at baseline, 4 weeks, and 3 months after donation. IFN-g
oups per peptide pool according to the number of spots per well (spw) after
(<50 and > 10 spw), and nonresponders (NR) ( 10 spw). The PBMCs were
mo) after donation. The ﬁgure shows only data for donors categorized as high
on: n ¼ 9; EBV EBNA-1: n ¼ 5; EBV LPM2 A: n ¼ 3; EBV BZLF1: n ¼ 10). Data are
and frozen PBMCs thawed 4 weeks and 3 months after donation in any of the
C. Sukdolak et al. / Biol Blood Marrow Transplant 19 (2013) 1480e14921490immunodominant antigens available in GMP quality aswell as
other viruses, such as polyoma virus BK, human herpesvirus 6,
and invasive fungal pathogens such as Aspergillus.
Selection of Suitable T Cell Donors is one of the Most
Critical Steps to Isolate Sufﬁcient Numbers of Clinical
Grade T Cells
Prescreening of potential T cell donors by multimer
staining, intracellular cytokine staining and/or IFN-g ELISpot
assay is essential and critical for successful T cell therapy.
After conﬁrmatory HLA and serology typing, in our institute,
a donor is chosen based on the frequency of IFN-gþ/CD3þ T
cells obtained by cytokine secretion assay (Figure 4) after
short stimulation with the antigen of interest (>.01% CD3þ/
IFN-gþ T cells). In a recent report, stem cell donors were
considered eligible for generation of EBNA-1especiﬁc
T-lymphocytes if the number of EBV-speciﬁc T cells exceeded
.01% of the CD3þ lymphocytes [12]. Speciﬁc T cells directed
against less immunodominant antigens, such as EBNA-1
peptide pool, were isolated in sufﬁcient numbers (2.5 
104 cells/kg in HLA-matched and 5  103 cells/kg in HLA-
mismatched settings) from 1  109 PBMCs by using the
cytokine secretion system. If the ﬁnal numbers of enriched
cells are too low, the reduction of the elution volume might
be an option to keep the cells viable. In a multicenter trial of
Feuchtinger et al., 18 patients were treated after allogeneic
HSCT with polyclonal CMV-speciﬁc T cells isolated from
haploidentical or unrelated donors [7]. These cells were
generated by in vitro stimulationwith CMVpp65, followed by
isolation of IFN-g-secreting cells in a centralized GMP facility
and then shipped to the respective hospitals.
Since April 2013, antigen-speciﬁc T cells isolated by the
IFN-g Cytokine Capture System are classiﬁed as advanced-
therapy medicinal product by the Committee for Advanced
Therapies of the European Medicines Agency (www.ema.
europa.eu/docs/en_GB/document_library/Report/2013/05/
WC500143582.pdf). As a consequence, broad and detailed
analysis of the speciﬁcity and functionality of the isolated T
cells are necessary to deﬁne proper biomarkers for set-up of
a GMP-compliant quality control. Next to the IFN-g-capture
system (Cytokine Capture System), the reversible Streptamer
technology is a second main approach, which has been also
successfully used to isolate clinical-grade virus-speciﬁc CD8þ
T cells [26]. Streptamer is currently the only pMHC multimer
used in adoptive immunotherapy, and according to medical
law, streptamers are not considered to be drugs, but rather
adjuvants. In the study of Schmitt and colleges (2011), they
demonstrated the successful treatment of 2 patients with
HLA-B07þ/CMVpp65especiﬁc CD8þ T cells and HLA-A*24þ/
CMVpp65-speciﬁc CD8þ T cells, respectively [23]. A drastic
increase from 0 to 27.1% (patient 1, within 28 days) and .03%
to .48% (patient 2, day þ166) of donor-derived CMVpp65-
speciﬁc effector T cells with no acute toxicity of the T cell
infusion, as well as no long-term toxicity of the procedure,
observed. The European Medicines Agency classiﬁed prod-
ucts of antigen-speciﬁc streptamer-isolated CD8 þ donor
lymphocytes intended for the treatment of infectious
diseases as non-advanced therapy medicinal products. In
Germany and Great Britain, the regulatory authorities
approved clinical trials with streptamer-selected cells, in
which the streptamer reagents were not produced under
GMP conditions. Clinically the adoptive transfer of highly
pure donor-derived CMV-speciﬁc CD8þ T cells resulted in
a persistent clearance of the CMV antigenemia, without
further high-level CMV reactivation.Need for Third-party T Cell Donors
Recent studies have shown that granulocyte colonye
stimulating factor mobilization might negatively inﬂuence
the functional activity of T cells [49,50], suggesting that
antiviral memory T cells from stem cell donors might not be
the best source. Additionally, we found that in some donors,
no antiviral T cells are detectable despite seropositivity, and
that serological testing by the standard ELISA technique
gives false-positive results in approximately 10% of donors.
Furthermore, for patients receiving allogeneic cord blood
transplant or a transplant from a virus-seronegative donor
[51], partially HLA-matched virus-speciﬁc T cells from
healthy seropositive third-party donors are a viable option.
In this context, GVHD and alloreactivity remain dreaded side
effects [52,53]. However, recent studies have shown that the
transfer of partially HLA-mismatched virus-speciﬁc T cells is
efﬁcacious and safe [6-8,10-12,43,54-56]. Consequently, the
use of third-party donors combined with rapid direct isola-
tion methods (IFN-g secretion assay, pMHC multimer tech-
nology) might be a promising way to supply antigen-speciﬁc
effector cells for the treatment of potentially life-threatening
infections after transplantation. Therefore, we are currently
establishing an allogeneic T cell donor registry, which will
document each donor’s HLA type (class I and II), virus
serology (ADV, CMV, EBV), virus-speciﬁc T cell frequencies,
best T cell detection method, and results from functional and
alloreactivity assays. The registry will be integrated in the
currently used HLA database (HLA system) of the Institute for
Transfusion Medicine. It will provide links to stem cell donor
registries as well as to Eurotransplant. This registry of HLA-
typed allogeneic T cell donors, who are characterized for
virus-speciﬁc T cells ﬁrst by ELISpot and then undergo
a detailed phenotypic and functional analysis using pMHC
multimer staining and cytokine secretion assays, will ensure
the rapid availability of T cells for virus-associated diseases in
transplant recipients without an adequate T cell donor. The
consolidated ﬁndings of this study will have signiﬁcant
implications for the analysis and selection of stem cells as
well as potential T cell donors.ACKNOWLEDGMENTS
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